Vertex Pharmaceuticals Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −2.98%.
Did VRTX Beat Earnings? Q4 2025 Results
Vertex Pharmaceuticals delivered a standout fourth quarter, posting non-GAAP EPS of $5.03 against a consensus estimate of $4.40, a beat of 14.28%, while revenue of $3.19 billion topped expectations by 4.56% and climbed 15.2% year over year. The headline driver was a powerful combination of continued strength in the company's cystic fibrosis franchise, particularly the ongoing U.S. rollout of ALYFTREK, and a lower effective tax rate that included a one-time benefit from previously deferred tax credits. Beyond the CF core, newer products added meaningful texture to the quarter: CASGEVY generated $54.30 million in revenue with 30 patient infusions, while JOURNAVX contributed $26.70 million following more than 550,000 prescriptions written since its March launch, signaling early commercial diversification taking hold. Looking ahead, Vertex guided FY 2026 revenue of $12.95 billion to $13.10 billion, with non-CF products expected to contribute at least $500 million, a threshold that underscores how meaningfully the company's growth story is broadening beyond its legacy franchise.
- Continued strong CF patient demand including ALYFTREK adoption
- Higher realized net prices in CF versus prior year
- Modest benefit from CF channel inventory in Q4
- Contributions from CASGEVY and JOURNAVX commercial launches
- Lower effective tax rate due to one-time benefit from recognition of previously deferred tax credits
“2025 marked a year of strong revenue growth, commercial diversification, and pipeline advancement. Our focus in 2026 remains on executing across the CF franchise, bringing CASGEVY to more patients around the globe and continuing to launch JOURNAVX, as we also prepare for the anticipated near-term commercialization of povetacicept in IgAN. With expanding leadership in CF, exciting commercial momentum, and multiple mid- and late-stage programs advancing, Vertex is well positioned to deliver long-term value for patients and shareholders.”
Vertex Pharmaceuticals CEO, on the earnings call
Forward Guidance & Outlook
Vertex provided FY 2026 total revenue guidance of $12.95 billion to $13.1 billion, including $500 million or more in revenue from non-CF products. The guidance assumes continued CF growth including the ongoing U.S. rollout and ex-U.S. launches of ALYFTREK, increased CASGEVY patient infusions through Vertex's global ATC network, and growth in JOURNAVX prescriptions and revenue. Combined non-GAAP R&D, AIPR&D, and SG&A expenses are guided at $5.65 billion to $5.75 billion, with approximately $100 million of AIPR&D expenses. Non-GAAP effective tax rate is expected at 19.5% to 20.5%. Combined GAAP R&D, AIPR&D, and SG&A expenses are guided at $6.3 billion to $6.45 billion. The company noted an immaterial tariff cost impact in 2026 based on currently known rates.
VRTX YoY Financials
VRTX Revenue by Segment
VRTX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.